FDA requires warning on GLP1 drugs over rare eye condition
Nov 16, 2026
FDA now requires warning labels for GLP-1 medications
The Food and Drug Administration is requiring GLP-1 agonist medications to carry a warning about a potential increased risk of a rare, serious eye condition.
The warning follows a study published in the journal Nature that found an associat
ion between some of the medications and nonarteritic anterior ischemic optic neuropathy, or NAION. The study reviewed more than 120 cases and more than 130 people in trials, including people who took a medication and people in control groups. It identified 15 cases of the eye condition, with more cases among people taking a GLP-1 agonist medication, said Dr. Janel Gordon, a WISH-TV medical expert.
Gordon discussed the condition and the study with WISH-TV anchor Gina Glaros on Monday.
NAION is caused by decreased blood flow to the front of the optic nerve, Gordon said. The optic nerve carries visual information from the eyes to the brain. Reduced blood flow can lead to sudden vision loss in one eye.
People may notice blind spots, tunnel vision or distorted colors, often upon waking, Gordon said. The condition is rare but serious.
Patients should discuss their medical conditions, medications and preferences with their healthcare providers when considering a GLP-1 medication, Gordon said. That includes whether they are comfortable with an injection or an oral medication and whether they can take a medication daily or weekly.
People with diabetes or high blood pressure, both of which can be risk factors for NAION, should tell their providers about their medications and any changes in dose or frequency, Gordon said. GLP-1 medications, including tirzepatide and semaglutide, can lower blood pressure, which could contribute to the eye condition. But diabetes and high blood pressure are themselves risk factors, so the available evidence does not establish that the medications cause NAION. More research is needed, she said.
The FDA warning is not a boxed warning, but it must be included with GLP-1 medications, Gordon said. Providers should discuss it with patients along with other possible side effects.
People taking a GLP-1 medication who experience symptoms such as sudden vision loss, blind spots, tunnel vision or distorted colors should contact a healthcare provider immediately, Gordon said. The symptoms should prompt an urgent referral to an ophthalmologist or other eye specialist.
...read more
read less